Evidence map›Paper›PMID 31612314›Full record

ReviewMolecular diagnosis & therapy2019

Current Evidence on Potential Uses of MicroRNA Biomarkers for Migraine: From Diagnosis to Treatment.

Parisa Gazerani

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Publisher
In one paragraph

Review in Molecular diagnosis & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05891808 (Expression of miR-155 in Migraine), which is not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05891808 unknown statusnot on this mapstarted 2020, after this paper: background citation

Expression of miR-155 in Migraine: Association With Different Phenotypes and Disease Severity

TypeobservationalSponsorIRCCS National Neurological Institute "C. Mondino" FoundationRan2020 to 2024Enrolled90ConditionsMigraine, Headache, Pain, Chronic Migraine
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. The Role of MicroRNA in Migraine: A Systemic Literature Review.Cellular and molecular neurobiology · 2023
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Migraine and Stroke: A Scoping Review.Journal of clinical medicine · 2024
    Article
  10. Review
  11. Article
  12. Serological Biomarkers of Chronic Migraine.Current pain and headache reports · 2023
    Review
  13. The Epigenetics of Migraine.International journal of molecular sciences · 2023
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Parisa GazeraniDepartment of Health Science and Technology, Faculty of Medicine, Aalborg University, Frederik Bajers Vej 3B, 9220, Aalborg East, Denmark. gazerani@hst.aau.dk.ORCID http://orcid.org/0000-0003-0109-3600
Aalborg University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Migraine is a disabling and recurrent neurological disorder characterized by headache attacks that are often accompanied by sensory and motor disturbances. The value and importance of reliable biomarkers in migraine have been long recognized and a diverse range of biomarkers from biological samples to electrophysiological patterns and brain imaging has been proposed. There is still no consensus on specific biomarker(s) for migraine. Ideally, not a single but a battery of biomarkers would provide a multidisciplinary way to understand and treat migraine better. Translational research has witnessed an escalating number of studies on microRNAs (miRNAs) during the last decade. Identification of the first miRNA occurred in 1993, and currently more than 2000 human miRNAs have been recognized. miRNAs are a group of endogenous small non-coding molecules that play a key role in post-transcriptional gene processes and hence are involved in health and disease. miRNAs have already been found to be involved in the onset and progression of several human disorders including chronic pain conditions; however, there have been far fewer studies in migraine and other headaches. Current evidence does suggest that miRNAs play a role in migraine and its relief and hence these molecules are proposed as potential migraine biomarkers. This review updates the current evidence for the role of miRNAs in migraine; including their potential as biomarkers, with a role in understanding of its pathogenesis, the population at risk, diagnosis, patient stratification, chronification risk factors, response to treatments, and miRNA-based therapeutic options. Limitations exist and further research is required to completely unwrap the potential of miRNAs in migraine research and practice.

Indexed as

Evidence-Based MedicineGene Expression RegulationGenetic MarkersHumansMicroRNAsMigraine DisordersMolecular Targeted TherapyTranslational Research, BiomedicalGenetic MarkersMicroRNAs

Identifiers

PMID31612314
OpenAlexW2979943295

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.